Company Profile
NervGen Pharma Stock Price, News & Analysis
- Ticker:
- NGEN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Canada and listed in the U
Stock performance
1.72 USD (+2.38%)
Close
Last updated: August 6, 2026
212M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, NGEN closed up 2.38% at $1.72. No new same-company headline was identified in the current news window.
Company overview
Neuroreparative Therapeutics Company
NervGen Pharma develops first-in-class neuroreparative therapies for spinal cord injury and other neurological trauma and disease. Its objective is to promote nervous-system repair and improve function, independence, and quality of life.
NVG-291 Mechanism and Positioning
Lead candidate NVG-291 is a subcutaneously administered neuroreparative peptide targeting the inhibitory CSPG-PTPσ pathway. The program has received FDA Fast Track designation and EMA Orphan Drug designation for spinal cord injury.
Registrational Path in Chronic Tetraplegia
Following an End-of-Phase 2 meeting, NervGen reached alignment with the FDA on key parameters for the RESTORE registrational study of NVG-291 in chronic tetraplegia.
Clinical Evidence in Spinal Cord Injury
The CONNECT SCI program evaluates whether NVG-291 can improve neurological and functional outcomes in people living with spinal cord injury. Biomarker, motor-function, and gait analyses from this work inform the design and endpoints of the registrational program.
Expansion Beyond Spinal Cord Injury
Because CSPG-PTPσ signaling is implicated in inhibited nervous-system repair, NervGen is evaluating additional neurological trauma and disease indications for NVG-291. The company plans to prioritize opportunities based on biological rationale, development feasibility, and available resources.
Future catalysts
Site activation has begun for the RESTORE registrational study, which was expected to start in mid-2026.
Results from an independent, blinded biomechanical gait analysis in the Phase 1b/2a CONNECT SCI study were expected in the second quarter of 2026.
NervGen expected to disclose a prioritization framework in mid-2026 for expanding NVG-291 into additional neurological trauma and disease indications.
Recent news
- 01
- 02
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
Source: NervGen Pharma
- 03
NervGen Announces Proposed Public Offering of Securities
Source: NervGen Pharma
- 04
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
Source: NervGen Pharma
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of NervGen Pharma (NGEN)?
NervGen Pharma (NGEN) most recently closed at 1.72 USD, a +2.38% move versus the previous session.
What is the market cap of NervGen Pharma (NGEN)?
NervGen Pharma currently has a market capitalization of 212M USD on BioPharmSignal.
What does NervGen Pharma do?
Neuroreparative Therapeutics Company NervGen Pharma develops first-in-class neuroreparative therapies for spinal cord injury and other neurological trauma and disease. Its objective is to promote nervous-system repair and improve function, independence, and quality of life. NVG-291 Mechanism and Positioning Lead candidate NVG-291 is a subcutaneously...
On which exchange is NGEN stock listed?
NervGen Pharma (NGEN) is associated with NASDAQ, Canada and listed in the U, Biopharma.
What is NVG-291?
NervGen expected to disclose a prioritization framework in mid-2026 for expanding NVG-291 into additional neurological trauma and disease indications.
Which conditions is NervGen Pharma targeting with NVG-291?
NervGen expected to disclose a prioritization framework in mid-2026 for expanding NVG-291 into additional neurological trauma and disease indications.
How does NervGen Pharma describe recent progress with NVG-291?
NervGen expected to disclose a prioritization framework in mid-2026 for expanding NVG-291 into additional neurological trauma and disease indications.
What is CSPG-PTP?
NVG-291 Mechanism and Positioning Lead candidate NVG-291 is a subcutaneously administered neuroreparative peptide targeting the inhibitory CSPG-PTPσ pathway.